Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s traded shares stood at 2.9 million during the last session, with the company’s beta value hitting 1.15. At the close of trading, the stock’s price was $16.36, to imply an increase of 14.49% or $2.07 in intraday trading. The DNA share’s 52-week high remains $64.40, putting it -293.64% down since that peak but still an impressive 67.85% since price per share fell to its 52-week low of $5.26. The company has a valuation of $940.35M, with an average of 1.36 million shares in intraday trading volume over the past 10 days and average of 1.40 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Ginkgo Bioworks Holdings Inc (DNA), translating to a mean rating of 3.83. Of 5 analyst(s) looking at the stock, 2 analyst(s) give DNA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
After registering a 14.49% upside in the last session, Ginkgo Bioworks Holdings Inc (DNA) has traded red over the past five days. The 5-day price performance for the stock is 33.55%, and 41.77% over 30 days. With these gigs, the year-to-date price performance is 66.60%. Short interest in Ginkgo Bioworks Holdings Inc (NYSE:DNA) saw shorts transact 7.83 million shares and set a 5.41 days time to cover.
The extremes give us $7 and $7 for target low and target high price respectively. As such, DNA has been trading 57.21% off suggested target high and 57.21% from its likely low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Looking at statistics comparing Ginkgo Bioworks Holdings Inc share performance against respective industry, we note that the company has outperformed competitors. Ginkgo Bioworks Holdings Inc (DNA) shares are 34.63% up over the last 6 months, with its year-to-date growth rate higher than industry average at 35.77% against 16.00%.
DNA Dividends
Ginkgo Bioworks Holdings Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
Ginkgo Bioworks Holdings Inc insiders hold 6.68% of total outstanding shares, with institutional holders owning 68.94% of the shares at 73.88% float percentage. In total, 68.94% institutions holds shares in the company, led by VIKING GLOBAL INVESTORS LP. As of 2024-06-30, the company held over 143.09 million shares (or 7.1383% of shares), all amounting to roughly $47.83 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 138.96 million shares, or about 6.9327% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $46.46 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Ginkgo Bioworks Holdings Inc (DNA) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.17 shares. This is just over 2.59% of the total shares, with a market valuation of $19.12 million. Data from the same date shows that the other fund manager holds a little less at 526.35, or 1.16% of the shares, all valued at about 8.61 million.
